Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;27(6):1607-1615.
doi: 10.3201/eid2706.210128.

HIV Infection as Risk Factor for Death among Hospitalized Persons with Candidemia, South Africa, 2012-2017

HIV Infection as Risk Factor for Death among Hospitalized Persons with Candidemia, South Africa, 2012-2017

Nelesh P Govender et al. Emerg Infect Dis. 2021 Jun.

Abstract

We determined the effect of HIV infection on deaths among persons >18 months of age with culture-confirmed candidemia at 29 sentinel hospitals in South Africa during 2012-2017. Of 1,040 case-patients with documented HIV status and in-hospital survival data, 426 (41%) were HIV-seropositive. The in-hospital case-fatality rate was 54% (228/426) for HIV-seropositive participants and 37% (230/614) for HIV-seronegative participants (crude odds ratio [OR] 1.92, 95% CI 1.50-2.47; p<0.001). After adjusting for relevant confounders (n = 907), mortality rates were 1.89 (95% CI 1.38-2.60) times higher among HIV-seropositive participants than HIV-seronegative participants (p<0.001). Compared with HIV-seronegative persons, the stratum-specific adjusted mortality OR was higher among HIV-seropositive persons not managed in intensive care units (OR 2.27, 95% CI 1.47-3.52; p<0.001) than among persons who were (OR 1.56, 95% CI 1.00-2.43; p = 0.05). Outcomes among HIV-seropositive persons with candidemia might be improved with intensive care.

Keywords: Candida; Candida albicans; HIV/AIDS and other retroviruses; South Africa; candidemia; fungi; mortality; sepsis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart demonstrating selection of 1,040 cases of candidemia from a 6-year surveillance period for secondary data analysis, South Africa, 2012–2017.
Figure 2
Figure 2
Kaplan-Meier analysis for 1,023 participants with candidemia during a 30-day period after the diagnosis of culture-confirmed candidemia by HIV infection status (outcome date missing for 17 participants), South Africa, 2012–2017. HIV = 0: HIV-seronegative; HIV = 1: HIV-seropositive; p value for log-rank test <0.001.

References

    1. van Schalkwyk E, Mpembe RS, Thomas J, Shuping L, Ismail H, Lowman W, et al.; GERMS-SA. GERMS-SA. Epidemiologic shift in candidemia driven by Candida auris, South Africa, 2016–2017. Emerg Infect Dis. 2019;25:1698–707. 10.3201/eid2509.190040 - DOI - PMC - PubMed
    1. Tsay SV, Mu Y, Williams S, Epson E, Nadle J, Bamberg WM, et al. Burden of Candidemia in the United States, 2017. Clin Infect Dis. 2020;71:e449–53. 10.1093/cid/ciaa193 - DOI - PubMed
    1. Lee RA, Zurko JC, Camins BC, Griffin RL, Rodriguez JM, McCarty TP, et al. Impact of infectious disease consultation on clinical management and mortality in patients with candidemia. Clin Infect Dis. 2019;68:1585–7. 10.1093/cid/ciy849 - DOI - PubMed
    1. Kim SH, Yoon YK, Kim MJ, Sohn JW. Clinical impact of time to positivity for Candida species on mortality in patients with candidaemia. J Antimicrob Chemother. 2013;68:2890–7. 10.1093/jac/dkt256 - DOI - PubMed
    1. Keighley C, Chen SCA, Marriott D, Pope A, Chapman B, Kennedy K, et al. Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study. BMC Infect Dis. 2019;19:445. 10.1186/s12879-019-4065-5 - DOI - PMC - PubMed

Publication types

LinkOut - more resources